{"nctId":"NCT00326118","briefTitle":"Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.","startDateStruct":{"date":"2006-06-01"},"conditions":["Haemophilus Influenzae Type b","Neisseria Meningitidis"],"count":433,"armGroups":[{"label":"Meningitec + Hiberix Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Priorix™","Biological: Hiberix™","Biological: Meningitec™"]},{"label":"Menitorix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Haemophilus influenzae type b and meningococcal serogroup C (vaccine)","Biological: Priorix™"]}],"interventions":[{"name":"Haemophilus influenzae type b and meningococcal serogroup C (vaccine)","otherNames":["Hib-MenC","Menitorix™"]},{"name":"Priorix™","otherNames":[]},{"name":"Hiberix™","otherNames":[]},{"name":"Meningitec™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPrimary phase:\n\n* Subjects whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.\n* A male or female between, and including, 12 and 18 months of age at the time of vaccination.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Free of obvious health problems as established by medical history and clinical examination before entering into the study.\n* Previously completed routine childhood vaccinations to the best of his/her parents'/guardians knowledge.\n* Having completed primary vaccination with two doses of Haemophilus influenzae type b outer membrane protein (Hib-OMP) containing vaccine OR three doses of diphtheria, tetanus, acellular pertussis and Haemophilus influenzae type b (DTPa/Hib) containing vaccine at least 6 months before the study start.\n\nLong-term persistence phase:\n\n\\- Having participated in the vaccination study 106445\n\nExclusion Criteria:\n\nFor the primary vaccination phase:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Chronic administration (defined as more than 14 days) or planned administration of immuno-suppressants or other immune-modifying drugs within six months prior to vaccination.\n* Planned administration/administration of a vaccine not foreseen by the protocol during the period starting from 30 days before vaccination and ending 30 days after vaccination.\n* Administration of a meningococcal vaccine not foreseen by the study protocol during the period starting at birth and ending at first dose.\n* Previous administration of a booster dose of Hib vaccine.\n* Previous vaccination against measles, mumps, rubella.\n* History of H. influenzae type b, meningococcal serogroup C and/or confirmed measles, mumps or rubella diseases.\n* Known exposure to measles, mumps or rubella within 30 days prior to the start of the study.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.\n* A family history of congenital or hereditary immunodeficiency.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.\n* Major congenital defects or serious chronic illness.\n* History of neurological disorders or more than one episode of febrile convulsion.\n* Acute disease at the time of enrolment.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.\n\nAdditional exclusion criteria for the long-term persistence phase: to be checked each year.\n\n* Previous administration of a booster dose of Hib, meningococcal serogroup C vaccines.\n* History of H. influenzae type b, meningococcal serogroup C diseases.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"18 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)","description":"Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of short-term protection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"292","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer","description":"rSBA-MenC titers greater than or equal to 1:8 titer are indicative of seroprotection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"280","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values","description":"rSBA-MenC titers cut-off values assessed were greater than or equal to (≥) 1:8 (indicative of seroprotection) and ≥ 1:128 titers.\n\nFunctional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the Public Health England (PHE), formerly known as Health Protection Agency (HPA), at Year 4, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"216","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"247","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values","description":"rSBA-MenC titers cut-off values assessed were greater than or equal to (≥)1:8 (indicative of seroprotection) and 1:128 titers. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers","description":"Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the PHE at year 4 after vaccination, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"482.8","spread":null},{"groupId":"OG001","value":"621.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"63.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"30.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"21.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers","description":"Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null},{"groupId":"OG001","value":"8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values","description":"Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"252","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"235","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"286","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"209","spread":null},{"groupId":"OG001","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values","description":"Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.438","spread":null},{"groupId":"OG001","value":"0.472","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.652","spread":null},{"groupId":"OG001","value":"73.976","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.550","spread":null},{"groupId":"OG001","value":"4.802","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.234","spread":null},{"groupId":"OG001","value":"2.751","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.116","spread":null},{"groupId":"OG001","value":"2.964","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations","description":"Concentrations are given as Geometric Mean Concentrations (GMCs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.131","spread":null},{"groupId":"OG001","value":"2.537","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Above the Cut-off Values","description":"Anti-PSC antibody concentration cut-off values assessed include greater than or equal to (≥) 0.30 µg/mL and ≥ 2.0 µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"290","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"289","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-polysaccharide C (Anti-PSC) Antibody Concentrations","description":"Concentrations given as Geometric Mean Concentrations (GMCs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.69","spread":null},{"groupId":"OG001","value":"7.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local and General Symptoms","description":"Solicited local symptoms assessed include pain, redness and swelling at the injection site.\n\nSolicited general symptoms assessed include drowsiness, fever (≥ 38°C), irritability and loss of appetite.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited Symptoms","description":"Unsolicited symptom: Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"217","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject.\n\nFor the long-term persistence phase (Years 1 through 5), only those SAEs that are determined by the investigator to have a causal relationship to the vaccination will be described individually.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":324},"commonTop":["Irritability","Redness","Drowsiness","Loss of appetite","Pain"]}}}